Curis Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Curis de 5.6% y 42.6% respectivamente, mientras que el BPA crecerá en un 30.8% al año.

Información clave

5.5%

Tasa de crecimiento de los beneficios

30.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	30.9%
Tasa de crecimiento de los ingresos	39.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	07 May 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:CUS0 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	11	-63	-53	-51	6
12/31/2025	9	-55	-49	-47	6
12/31/2024	10	-49	-47	-43	2
12/31/2023	10	-47	-38	-38	N/A
9/30/2023	10	-47	-41	-41	N/A
6/30/2023	10	-48	-46	-45	N/A
3/31/2023	10	-52	-50	-50	N/A
12/31/2022	10	-57	-55	-54	N/A
9/30/2022	10	-59	-51	-50	N/A
6/30/2022	11	-57	-47	-47	N/A
3/31/2022	11	-52	-41	-41	N/A
12/31/2021	11	-45	-38	-38	N/A
9/30/2021	11	-39	-35	-35	N/A
6/30/2021	10	-34	-32	-31	N/A
3/31/2021	10	-30	-30	-30	N/A
12/31/2020	11	-30	-26	-26	N/A
9/30/2020	11	-31	-26	-26	N/A
6/30/2020	11	-31	-27	-26	N/A
3/31/2020	11	-32	-28	-28	N/A
12/31/2019	10	-32	-26	-26	N/A
9/30/2019	9	-29	-26	-26	N/A
6/30/2019	9	-30	-27	-27	N/A
3/31/2019	10	-32	-27	-27	N/A
12/31/2018	10	-33	-30	-30	N/A
9/30/2018	11	-35	-33	-33	N/A
6/30/2018	11	-43	-41	-41	N/A
3/31/2018	10	-48	-43	-43	N/A
12/31/2017	10	-53	-49	-48	N/A
9/30/2017	9	-57	N/A	-50	N/A
6/30/2017	8	-70	N/A	-41	N/A
3/31/2017	8	-67	N/A	-43	N/A
12/31/2016	8	-60	N/A	-36	N/A
9/30/2016	7	-63	N/A	-37	N/A
6/30/2016	8	-40	N/A	-34	N/A
3/31/2016	8	-37	N/A	-30	N/A
12/31/2015	8	-59	N/A	-30	N/A
9/30/2015	8	-51	N/A	-24	N/A
6/30/2015	7	-51	N/A	-21	N/A
3/31/2015	10	-45	N/A	-19	N/A
12/31/2014	10	-19	N/A	-17	N/A
9/30/2014	9	-17	N/A	-18	N/A
6/30/2014	15	-14	N/A	-15	N/A
3/31/2014	15	-13	N/A	-11	N/A
12/31/2013	15	-12	N/A	-10	N/A
9/30/2013	15	-20	N/A	-17	N/A
6/30/2013	9	-22	N/A	-22	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CUS0 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CUS0 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CUS0 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (42.6% al año) de CUS0 crezcan más rápidamente que los del mercado German (5.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (42.6% al año) de CUS0 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CUS0 se prevé que sea elevada dentro de 3 años.

Curis Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Curis, Inc., Annual General Meeting, May 21, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$8.96 loss per share (vs US$12.14 loss in FY 2022)

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2022)

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$0.61 loss per share (vs US$0.50 loss in FY 2021)

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2021)

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 2Q 2021)

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020)

Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS

Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019)

Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021

Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

New 90-day high: €7.25

New 90-day high: €6.70

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million.

Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

New 90-day high: €1.17

Third quarter 2020 earnings released: US$0.11 loss per share

Curis, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021

Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting

New 90-day low - €0.74

First half earnings released

Curis, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million.

Curis, Inc. to Report Q2, 2020 Results on Aug 04, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento